A Comparison of Tamsulosin and Combination Therapy with Tamsulosin and Dutasteride in Patients with Benign Prostate Hyperplasia-Related Acute Urinary Retention
A total of 150 patientswho were initially admitted to the emergency department for BPH-associated AUR were selected.The urethral catheters were removed at the end of 3 days, and 96 patients who had a post-void residual urine volume of
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Objective: To investigate whether combination therapy is more effective than either monotherapyin reducing the relative risk for benign prostate hyperplasia (BPH)-related surgery in patients withacute urinary retention (AUR).Methods: We retrospectively reviewed recorded data of patients who were randomized intotwo groups according to medical treatment as tamsulosin monotherapy and tamsulosin withdutasteride combination therapy between June 2002 and February 2008.
📊
Temel Bulgular & Veri:Objective: To investigate whether combination therapy is more effective than either monotherapyin reducing the relative risk for benign prostate hyperplasia (BPH)-related surgery in patients withacute urinary retention (AUR).Methods: We retrospectively reviewed recorded data of patients who were randomized intotwo groups according to medical treatment as tamsulosin monotherapy and tamsulosin withdutasteride combination therapy between June 2002 and February 2008.
💡
Sonuç & Katkı:A total of 150 patientswho were initially admitted to the emergency department for BPH-associated AUR were selected.The urethral catheters were removed at the end of 3 days, and 96 patients who had a post-void residual urine volume of
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2002 Verileri
⚙️Değişkenler:Alan Parametreleri
Abstract
Objective: To investigate whether combination therapy is more effective than either monotherapyin reducing the relative risk for benign prostate hyperplasia (BPH)-related surgery in patients withacute urinary retention (AUR).Methods: We retrospectively reviewed recorded data of patients who were randomized intotwo groups according to medical treatment as tamsulosin monotherapy and tamsulosin withdutasteride combination therapy between June 2002 and February 2008. A total of 150 patientswho were initially admitted to the emergency department for BPH-associated AUR were selected.The urethral catheters were removed at the end of 3 days, and 96 patients who had a post-void residual urine volume of
🔖
Bu Makaleye Atıf Yap
TOKTAŞ, G., ÖZBİR, S., ATALAY, H. A., ALKAN, İ., CANAT, L., ÇAKIR, S. S. (2022). A Comparison of Tamsulosin and Combination Therapy with Tamsulosin and Dutasteride in Patients with Benign Prostate Hyperplasia-Related Acute Urinary Retention. European Archives of Medical Research, Cilt: 34 - Sayı: 3, 191–195. https://ajindex.com/articles/510471
Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9. [CrossRef] 2. Fitzpatrick JM. The natural history of benign prostatic hyperplasia. BJU Int 2006; 97(Suppl 2): 3-6. discussion 21-2. 3. Jacobsen SJ, Jacobsen DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7. [CrossRef] 4. Pickard R, Emberton M, Neal DE. The management of men with acute urinary retention. Br J Urol 1998; 81: 712-20. [CrossRef] 5. Chen JS, Chang CH, Yang WH, Kao YH. Acute urinary retention increases the risk of complications after transurethral resection of the prostate: a population-based study. BJU Int 2012; 50: 542-6. [CrossRef] 6. Armitage JN, Sibanda N, Cathcart PJ, Emberton M, van der Meulen JH. Mortality in men admitted to hospital with acute urinary retention: database analysis. BMJ 2007; 335: 1199-202. [CrossRef] 7. Taube M, Gajraj H. Trial without catheter following acute retention of urine. Br J Urol 1989; 63: 180-2. [CrossRef] 8. Spiro LH, Labay G, Orkin LA. Prostatic infarction: role in acute urinary retention. Urology 1974; 3: 345-7. [CrossRef] 9. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percentage area density of prostate smooth muscle. Prostate 1992; 21: 297-307. [CrossRef] 10. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179-84. [CrossRef] 11. McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5-alpha reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab 1992; 74: 505-8. [CrossRef] 12. Roehrborn CG, Boyle P, Nickel C, Hoefner K, Andriole Gon behalf of the ARIA3001, ARIA3002, and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434-41. [CrossRef] 13. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108: 388-94. [CrossRef] 1